Antimicrobial resistance

European $13.5 Billion Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration - Opportunity Analysis and Industry Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 20, 2021
Health, Pharmaceutical, Health sciences, Articles, Health, Pharmaceuticals policy, Veterinary medicine, Antibiotic resistance, Evolutionary biology, Antimicrobial resistance, Antibiotic misuse, Antibiotic, Drug resistance, Antibiotic use in livestock

b'The "European Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration: Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com\'s offering.\nThe European antibiotics market was valued at $11,561 million in 2019, and is projected to reach $13,529 million by 2027 at a CAGR of 1.9% from 2020 to 2027.\nThere is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases.

Key Points: 
  • b'The "European Antibiotics Market by Drug Class, Drug Origin, Spectrum of Activity and Route of Administration: Opportunity Analysis and Industry Forecast, 2019-2027" report has been added to ResearchAndMarkets.com\'s offering.\nThe European antibiotics market was valued at $11,561 million in 2019, and is projected to reach $13,529 million by 2027 at a CAGR of 1.9% from 2020 to 2027.\nThere is an increase in the demand for antibiotics, owing to rise in prevalence of infectious diseases.
  • In addition, development of novel approaches for new antibiotics for treating bacterial infections and a large number of clinical trials further drive the market growth.\nHowever, development of antibiotic resistance, driven by misuse of antibiotics and the time taken for the regulatory approval is projected to impede the market growth.\nOn the contrary, discovery of advanced prospect molecules and novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer significant profitable opportunities for the market players.\n'

Basilea awarded CARB-X grant of up to USD 2.7 million to develop novel-class antibiotic

Retrieved on: 
Wednesday, May 19, 2021
Health sciences, Health, Medicine, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Immunology, Antimicrobial resistance, Antibiotic, Drug resistance

The funding will support an ongoing Basilea research program to develop an antibiotic from a novel class for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.\nThe program aims to develop selective small-molecule inhibitors of DXR, an enzyme in the bacterial isoprenoid biosynthesis pathway.

Key Points: 
  • The funding will support an ongoing Basilea research program to develop an antibiotic from a novel class for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.\nThe program aims to develop selective small-molecule inhibitors of DXR, an enzyme in the bacterial isoprenoid biosynthesis pathway.
  • Laurenz Kellenberger, Chief Scientific Officer, said: \xe2\x80\x9cThe medical problem of antimicrobial resistance keeps increasing.
  • Therefore, new antibiotics are urgently needed that will be able to address resistance that is growing against current treatment options.
  • We are delighted to be partnering with CARB-X for the development of truly innovative antibiotics directed against this unexploited bacterial target.

Accelerate Diagnostics to Participate in William Blair 41st Annual Growth Stock Conference on June 3, 2021

Retrieved on: 
Wednesday, May 19, 2021
Health sciences, Articles, Branches of biology, Antibiotics, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antibiotic sensitivity testing, Infection, Blood culture

b'TUCSON, Ariz., May 19, 2021 /PRNewswire/ --Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today thatChief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will present virtually at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m. Central Time.\nA live audiocast of the session will be accessible through the company\'s investor relations website at ir.axdx.com .

Key Points: 
  • b'TUCSON, Ariz., May 19, 2021 /PRNewswire/ --Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today thatChief Executive Officer, Jack Phillips, and Chief Financial Officer, Steve Reichling, will present virtually at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 12:00 p.m. Central Time.\nA live audiocast of the session will be accessible through the company\'s investor relations website at ir.axdx.com .
  • A replay of the audiocast will be available for at least 30 days following the conference.\nAccelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis.
  • The Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for serious infections.
  • The FDA-cleared system and kit fully automate sample preparation steps, enabling phenotypic antibiotic susceptibility results in about 7 hours directly from positive blood cultures.

Spero Therapeutics to Participate at the Berenberg Conference USA

Retrieved on: 
Thursday, May 13, 2021
Health sciences, Articles, Health, Prodrugs, Tebipenem, Carbapenem, Multiple drug resistance, Antimicrobial resistance, Antibiotic

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA, taking place virtually from May 18 \xe2\x80\x93 20, 2021.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA, taking place virtually from May 18 \xe2\x80\x93 20, 2021.
  • Details for the fireside chat are as follows:\nA webcast of the fireside chat may also be accessed through Spero Therapeutics\xe2\x80\x99 website ( www.sperotherapeutics.com ) on the \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d page under the \xe2\x80\x9cInvestors and Media\xe2\x80\x9d tab.
  • A replay of the fireside chat will be archived on the website for 90 days following the conclusion of the event.\nSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.\nSpero\xe2\x80\x99s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).
  • In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.\nSpero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.\nSpero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.\n'

Global Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology 2021-2025, with 30+ Company Profiles - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 12, 2021
Other Science, Science, Health sciences, Articles, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Life sciences, Antimicrobial resistance, Antibiotic, Antimicrobial, Infection

b'The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, with Executive Guides and Customization - 2021 to 2025" report has been added to ResearchAndMarkets.com\'s offering.\nDiagnostics are leading the charge in reducing the threat posed by antimicrobial resistance.

Key Points: 
  • b'The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, with Executive Guides and Customization - 2021 to 2025" report has been added to ResearchAndMarkets.com\'s offering.\nDiagnostics are leading the charge in reducing the threat posed by antimicrobial resistance.
  • Will these technologies solve the problem before new antibiotics come along?
  • New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market.\nThis report provides a plain language understanding of the different ways pathogens, and infections can be diagnosed.
  • The report has identified the 6 Key Large Pathogen Opportunities in this space and developed market forecasts.

Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing

Retrieved on: 
Tuesday, May 11, 2021
Professional services, Health, Infectious diseases, Finance, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Life sciences, Articles, Bacteriophage, Biology, Antimicrobial resistance, Drug resistance, Multiple drug resistance, Antibiotic, Pathogen, Therapy

b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.

Key Points: 
  • b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.
  • Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor.
  • Proceeds of this financing will be used to accelerate clinical development of PhageBank\xe2\x84\xa2 phage therapies, as well as for general corporate purposes.\nAPT\xe2\x80\x99s PhageBank\xe2\x84\xa2 technology is a growing collection of hundreds of bacteriophage, collectively providing broad spectrum coverage against six of the highest priority multi-drug resistant bacterial pathogens.
  • Together, we believe we can bring PhageBank\xe2\x84\xa2 therapy into the mainstream, and work to solve one of the key challenges facing modern medicine, the growing problem of antibiotic-resistant bacteria.\xe2\x80\x9d\nAdaptive Phage Therapeutics is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic

Retrieved on: 
Monday, May 10, 2021
Biotechnology, Infectious diseases, Health, Science, Research, Infectious causes of cancer, Medical specialties, Gonorrhea, Clinical medicine, Medicine, Sexually transmitted diseases and infections, Chlamydiae, Pathogenic bacteria, Neisseria gonorrhoeae, Antimicrobial resistance, Neisseria, Chlamydia

SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones.

Key Points: 
  • SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones.
  • Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae, while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments.
  • SpeeDx will utilize their newly patented InSignia\xe2\x84\xa2 technology to both assess the presence of active bacterial infection and AMR status.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.

First Light Diagnostics Appoints Joanne Spadoro as Chief Executive Officer

Retrieved on: 
Wednesday, May 5, 2021
Articles, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Evolutionary biology, Life sciences

b'CHELMSFORD, Mass., May 5, 2021 /PRNewswire/ --First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening antibiotic-resistant infections, has named Joanne Spadoro, PhD, as President and Chief Executive Officer (CEO).\nAs the CEO of First Light Diagnostics, Dr. Spadoro will be responsible for leading the company through the development and commercialization phases of its novel pathogen identification and rapid antimicrobial susceptibility products.\n"The Board of Directors is delighted to have Dr. Spadoro as CEO leading the commercialization of First Light\'s medically impactful diagnostic products.

Key Points: 
  • b'CHELMSFORD, Mass., May 5, 2021 /PRNewswire/ --First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening antibiotic-resistant infections, has named Joanne Spadoro, PhD, as President and Chief Executive Officer (CEO).\nAs the CEO of First Light Diagnostics, Dr. Spadoro will be responsible for leading the company through the development and commercialization phases of its novel pathogen identification and rapid antimicrobial susceptibility products.\n"The Board of Directors is delighted to have Dr. Spadoro as CEO leading the commercialization of First Light\'s medically impactful diagnostic products.
  • Her extensive experience in all aspects of commercializing novel technologies and diagnostics productsand her outstanding leadership abilities make Dr. Spadoro an ideal CEO for First Light," said William Moffitt, Executive Chairman of First Light\'s Board of Directors.\nDr.
  • Spadoro is a well-regarded leader in the in vitro diagnostics and medical device fields.
  • The products will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics.

Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Medicine, Health, ESKAPE, Medical terminology, Antibiotic, XC2, Antimicrobial resistance, Infection, Drug resistance, The Pew Charitable Trusts

\xe2\x80\x9cAntimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug-resistance.

Key Points: 
  • \xe2\x80\x9cAntimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug-resistance.
  • The slight variation (+/-) between one experiment to the next is likely due to small variance in the sensitivity of the instruments used in detection.
  • Further to this designation, RECCE\xc2\xae 327 has been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the only synthetic polymer and sepsis drug candidate in development.\nRecce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recce\xe2\x80\x99s anti-infective pipeline seeks to exploit the unique capabilities of RECCE\xc2\xae technologies targeting synergistic, unmet medical needs.\n"

Spero Therapeutics to Provide Business Update and Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

Retrieved on: 
Thursday, April 29, 2021
Health sciences, Articles, Health, Prodrugs, Tebipenem, Carbapenem, Antimicrobial resistance, Antibiotic

b'CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\xc2\xa0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m.

Key Points: 
  • b'CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.\xc2\xa0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on May 6, 2021 at 4:30 p.m.
  • ET to report its first quarter 2021 financial results and provide an update on its business and pipeline.\nTo access the call please dial 877-705-6003 (domestic) or 201-493-6725 (international) and refer to conference ID 13718122.
  • The audio webcast can be accessed under \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d in the Investor and Media section of the Company\xe2\x80\x99s website at www.sperotherapeutics.com .
  • The archived webcast will also be available on Spero\xe2\x80\x99s website for 30 days following the call.\nSpero Therapeutics, Inc.\xc2\xa0is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.\nSpero\xe2\x80\x99s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).